International Isotopes Inc. Reveals Financial Performance for 2025
International Isotopes Inc. (OTCQB: INIS) has disclosed its financial performance for the recent third quarter, as well as the first nine months of 2025. The report shows a revenue figure of $3,277,816 for the third quarter, indicating a decrease of $646,628 or 16% compared to the same timeframe last year. However, when looking at the cumulative nine months, revenue climbed to $10,172,036, reflecting an increase of $173,901 or 2% from the previous year.
Challenges Leading to Revenue Fluctuations
The fluctuations in revenue can be attributed to various factors affecting the business operations. Notably, outages of raw materials for Theranostics Products occurred in multiple months, which significantly impacted supply. Additionally, the availability of raw materials for Calibration and Reference Products, especially Gd-153, was disrupted during key months.
Operational Impact of Material Shortages
Estimates suggest that these disruptions reduced sales by over $400,000 during the third quarter alone and more than $750,000 over the nine-month period. Despite these challenges, there was notable growth in sales of Calibration and Reference Products alongside Medical Devices, signaling resilience and adaptability within the company's operations.
Leadership Comments on Performance and Strategies
Shahe Bagerdjian, the President and CEO of International Isotopes Inc., commented on the recent challenges, particularly the raw material outages experienced in mid-year. He expressed optimism about the recent FDA approval of a new supplier for critical raw materials, stating that the company has seen an uptick in the number of customers for its Theranostics products.
Internal Improvements and Efficiency Enhancements
Additionally, the company reported a significant reduction in selling, general and administrative (SG&A) expenses, with a 24% decrease for the quarter and 11% year-to-date. Bagerdjian also noted ongoing efforts to enhance corporate governance to support the company's long-term sustainability.
Segment Performance Analysis
Focusing on the segments, revenue from Theranostics Products reached $5,176,740 for the first nine months, lower than last year’s $6,257,410, primarily due to supply chain disruptions. However, recovery efforts and FDA approval for additional supply sources are expected to improve future performance. Meanwhile, Calibration and Reference Products saw a considerable rise in revenue, climbing 57% year-over-year, primarily due to increased market demand following product enhancements.
Growth in Medical Devices Market
Another emerging segment for International Isotopes Inc. is Medical Devices, which reported revenues of $176,476 in the nine-month period, marking its successful market entry. This segment focuses on innovative products aimed at enhancing safety and efficacy across medical applications.
Future Outlook and Performance Measures
Looking ahead, International Isotopes Inc. anticipates continued revenue growth across its diversified segments as the supply chain normalizes and new products are introduced. The management is optimistic about achieving targeted financial results as operations stabilize.
Non-GAAP Financial Measures
The company's Non-GAAP EBITDA was reported at $14,985 for the first nine months, indicating a significant decrease from previous levels. Such performance metrics guide management in assessing operating trends while conveying valuable insights to shareholders.
Company Overview and Contact Information
Established in 1995, International Isotopes Inc. specializes in manufacturing radioisotope-focused products, including generic sodium iodide I-131 and a full range of calibration standards. With innovation and customer focus at the forefront, the company engages in both contract manufacturing and the supply of key pharmaceutical products.
For more detailed inquiries, International Isotopes Inc. can be contacted through their Investor Relations:
Email: ir@intisoid.com
Phone: 208.524.5300
Frequently Asked Questions
What financial results did International Isotopes Inc. report for 2025?
The company reported $3,277,816 in revenue for the third quarter and $10,172,036 for the nine months ended 2025.
What were the main challenges faced during this financial period?
The main challenges included raw material supply outages for core product lines, affecting overall revenue.
How did the company respond to operational challenges?
Management focused on optimizing internal processes, reducing SG&A expenses, and securing new suppliers to mitigate disruptions.
What are the growth prospects for International Isotopes Inc.?
With improved supply chains and new product introductions, the company anticipates steady revenue growth moving forward.
What product segments showed growth?
Calibration and Reference Products, along with Medical Devices, reported significant increases in revenue over the past year.
